Featured Research

from universities, journals, and other organizations

New Drug Aims To 'Seek And Destroy' Many Types Of Cancer

Date:
October 6, 2009
Source:
Scottsdale Healthcare
Summary:
A new drug designed to "seek and destroy" common cancers is being tested. The Phase I clinical trial is designed to evaluate the safety of EP-100 in adult patients with solid tumors whose tumor biopsies indicate that they have excessive LHRH receptors. Excessive LHRH receptors are found in a wide range of cancers, including breast, prostate, endometrial, pancreatic, ovarian, skin and testicular cancers.

A new drug designed to “seek and destroy” common cancers such as breast, prostate, endometrial, pancreatic, ovarian, skin and testicular cancers is being tested at TGen Clinical Research Services (TCRS) at Scottsdale Healthcare.

Related Articles


The Phase 1 clinical trial will help determine if EP-100 is safe and effective for use among patients with solid cancer tumors, with fewer side effects than chemotherapy or radiation treatment.

TCRS is a partnership of the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare. The partnership allows molecular and genomic discoveries made by TGen and others around the world to reach the patient bedside in the Virginia G. Piper Cancer Center at Scottsdale Healthcare as quickly as possible through clinical trials with agents directed at specific targets in patients’ tumors.

According to Ramesh K. Ramanathan, MD, principal investigator for the trial in Scottsdale, the drug is a membrane-disrupting peptide (tMDP) designed to “seek and destroy” cancer cells by targeting those with excessive luteinizing hormone releasing hormone (LHRH) receptors.

Excessive LHRH receptors are found in a wide range of cancers, including breast, prostate, endometrial, pancreatic, ovarian, skin and testicular cancers.

Mike Janicek, MD, a Gynecologist Oncologist who practices at the Virginia G. Piper Cancer Center at Scottsdale Healthcare said, “I am looking forward to participating in the study with EP100, especially for ovarian and uterine cancer patients. Often patients with advanced cancer will need new therapies and a targeted treatment like EP100 is the next frontier of research.”

The study is designed to evaluate the safety of EP100 and will enroll as many as 36 adult patients with solid tumors whose tumor biopsies indicate that they have excessive LHRH receptors.

EP-100 will be administered intravenously for three out of four weeks. Once the maximum tolerated dose has been established, additional subjects with specific diagnoses of either breast, ovarian, endometrial, pancreatic or prostate cancer will be enrolled. EP-100 is produced by Esperance Pharmaceuticals of Baton Rouge, La., and was culled from a range of drugs tested at TGen Drug Development Services (TD2) in Scottsdale.

“It brings with it a killer, a toxin. It’s a way of targeting a toxin to the cancer tumor cells,’’ said Dr. Steve Gately, president and chief scientific advisor at TD2. “Our goal would be to find that set of patients who are highly responsive; who have the greatest benefit. We’d like to accelerate the government approval for that agent.’’

The clinical trials could show that EP-100 is effective with certain types of cancer, Dr. Gately said. “Perhaps there is a genetic context under which certain patients may be more responsive. We want to find those patients.’’

Dr. Hector Alila, president of Esperance, said EP-100 has the potential to offer an improved safety and effectiveness over existing therapies, such as radiation or chemotherapy.

“Preclinical studies of EP-100 demonstrated this candidate’s efficacy across multiple indications in oncology, including aggressive cancers known to be resistant to the current standards of care and, importantly, studies of EP-100’s mechanism-of-action support that it targets and selectively kills cancer cells without harming normal cells,” Dr. Alila said.


Story Source:

The above story is based on materials provided by Scottsdale Healthcare. Note: Materials may be edited for content and length.


Cite This Page:

Scottsdale Healthcare. "New Drug Aims To 'Seek And Destroy' Many Types Of Cancer." ScienceDaily. ScienceDaily, 6 October 2009. <www.sciencedaily.com/releases/2009/10/091005161439.htm>.
Scottsdale Healthcare. (2009, October 6). New Drug Aims To 'Seek And Destroy' Many Types Of Cancer. ScienceDaily. Retrieved February 1, 2015 from www.sciencedaily.com/releases/2009/10/091005161439.htm
Scottsdale Healthcare. "New Drug Aims To 'Seek And Destroy' Many Types Of Cancer." ScienceDaily. www.sciencedaily.com/releases/2009/10/091005161439.htm (accessed February 1, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Sunday, February 1, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC: Get Vaccinated for Measles

CDC: Get Vaccinated for Measles

Reuters - US Online Video (Jan. 30, 2015) The CDC is urging people to get vaccinated for measles amid an outbreak that began at Disneyland and has now infected more than 90 people. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Obama To Outline New Plan For Personalized Medicine

Obama To Outline New Plan For Personalized Medicine

Newsy (Jan. 30, 2015) President Obama is expected to speak with drugmakers Friday about his Precision Medicine Initiative first introduced last week. Video provided by Newsy
Powered by NewsLook.com
NFL Concussions Down; Still on Parents' Minds

NFL Concussions Down; Still on Parents' Minds

AP (Jan. 30, 2015) The NFL announced this week that the number of game concussions dropped by a quarter over last season. Still, the dangers of the sport still weigh on players, and parents&apos; minds. (Jan. 30) Video provided by AP
Powered by NewsLook.com
U.S. Wants to Analyze DNA from 1 Million People

U.S. Wants to Analyze DNA from 1 Million People

Reuters - US Online Video (Jan. 30, 2015) The U.S. has proposed analyzing genetic information from more than 1 million American volunteers to learn how genetic variants affect health and disease. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins